Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa

BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Stewart, Balint, Jobarteh, Modou L, Sarge-Njie, Ramu, Alabi, Abraham, de Silva, Thushan, Peterson, Kevin, Peterson, Ingrid, Whittle, Hilton, Rowland-Jones, Sarah, Jaye, Assan, Cotten, Matthew, Mendy, Maimuna
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2011
נושאים:
Short Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3292846/
https://ncbi.nlm.nih.gov/pubmed/22195774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-4-561
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים